Price Target on Cancer Drug Co. Boosted
Source: Joseph Pantginis  (8/22/22)
The price target was increased by 66% to reflect the full potential opportunity of the biopharma's drug candidate for hepatocellular carcinoma, a key driver going forward, noted an H.C. Wainwright & Co. report. More >

Drug Developer Initiates Ph. 3 STGD1 Trial
Source: Streetwise Reports  (8/22/22)
Shares of Belite Bio Inc. traded 19% higher after the company reported it has initiated a pivotal Phase 3 clinical study in the U.S. for its LBS-008 for use in treating Stargardt disease. More >

Tech Wearables Firm Teams with Saudi IT Co in Smart City Buildout
Source: Streetwise Reports  (8/22/22)
A Vancouver-based firm just announced a partnership with the biggest publicly traded IT company in Saudi Arabia as it looks to provide hardware-assisted software solutions for the multi-billion-dollar new Smart City buildout happening in the Middle East. More >

Mining Co. With Four Assets Gains Finance Firm's Attention
Source: Patrick Smith  (8/19/22)
Analyst coverage was initiated on this Canadian mining explorer, which has significant land packages and multimillion ounces of gold in metals-rich areas of Papua New Guinea, noted a Jemini Capital report. More >

Solar Co. Exceeds Revenue Estimates in Q2
Source: Streetwise Reports  (8/19/22)
Shares of Canadian Solar Inc. traded 15% higher yesterday to a new 52-week high after the company reported Q2/22 financial results that highlighted a 62% YoY increase in revenue and raised the ranges of its FY/22 revenue estimates by $500 million. More >

New Drill Data from Gold Project Boost Resources
Source: Pierre Vaillancourt  (8/19/22)
Drill results Troilus Gold Corp. generated in the last four months at this property will be incorporated into the upcoming mineral resource update and prefeasibility study, noted a Haywood Securities report. More >

Biopharma Co. Gains FDA Approval for Oral MDD Drug
Source: Streetwise Reports  (8/19/22)
Shares of Axsome Therapeutics Inc. traded 39% higher after the company reported that the U.S. FDA granted approval for its AUVELITYâ„¢ making it the first oral N-methyl D-aspartate (NMDA) receptor antagonist authorized for treating major depressive disorder in adults. More >

Healthcare Co. Brings Treatment to Canadian Alcohol Addiction Market
Source: Streetwise Reports  (8/18/22)
One healthcare company in the U.K. is bringing its proprietary Ketamine-assisted treatment for Alcohol Use Disorder to Canada. It's the second deal the company has made with a North American clinic operator this week. Find out why this won't be the last one. More >

Green Tech Co. Says Plant's Environmental Permit on Track
Source: Streetwise Reports  (8/17/22)
The government in Ecuador is on track to grant an environmental permit for BacTech Environmental Corp.'s new bioleaching plant in September, the company says. More >

Biotech Co. To Receive 66% Funding From UK Gov.
Source: Clive Maund  (8/17/22)
Expert Clive Maund reviews the latest update with Awakn Life Sciences Corp., including its recent rise in stock volume and the announcement that the company is to receive 66% funding support from the UK government for the development of its ketamine-assisted therapy treatment for alcohol use disorders. More >

Gold Co.'s Target Price Boosted by $5 Per Share
Source: Joe Reagor  (8/17/22)
The new figure takes into account recently determined economics and upside of the world's largest undeveloped gold project along with future precious metals prices, noted a ROTH Capital Partners report. More >

Oil & Gas Co. Gets Clearance for 200 Mcf/Day Natural Gas Plant
Source: Streetwise Reports  (8/17/22)
Shares of Touchstone Exploration Inc. traded 16% higher after the company reported it received environmental approval for construction of a two hundred million cubic feet multi-well surface production facility in Trinidad. More >

Equipment Co.'s First Six Months 'The Strongest in Recent History'
Source: Chris Temple  (8/17/22)
Expert Chris Temple of The National Investor reviews the latest updates with Enterprise Group Inc., including the announcement of its second-quarter results. More >

Life Sciences Co. Gets Big Order for Livestock Feed Additive
Source: Joseph Gomes   (8/16/22)
This sale indicates the firm is continuing to forge a pathway into one of its large target markets, noted a Noble Capital Markets report. More >

Communications Co.'s 14-Point Strategy Drives Revenue Growth
Source: Chris Thompson  (8/16/22)
B2B communications and marketing solutions firm DATA Communications Management Corp. has implemented a five-year, 14-point strategic plan aimed at transitioning clients from print to digital services. eResearch Corp. stated in a research update that the plan is expected to generate both top-line growth and robust EBITDA margin expansion and mentioned that during Q1/22 the company posted its largest quarterly YoY revenue growth in four years. eResearch stated that it is maintaining its Buy rating on the company with a 12-month price target of CA$4.00. More >

Junior Explorer Pivots to Critical Minerals, Metals
Source: Streetwise Reports  (8/16/22)
Rover Metals Corp. is not getting out of its gold projects but has an eye on the future with a critical minerals and metals project in the Northwest Territories. More >

Co. Pursuing Ketamine for Addiction Forms Partnership
Source: Andrew Partheniou  (8/16/22)
In landing this first licensing deal, the life sciences firm "shows good progress towards a potentially high-margin business," noted a Stifel report. More >

Miner Intercepts 10.67 Meters of 1,339 G/T Silver at Flagship Project
Source: Streetwise Reports  (8/16/22)
Silver One Resources Inc. shares traded 14% higher after the silver mining firm reported that it intersected 48.77m of 332 g/t Ag and 0.39 g/t Au, which included 10.67m of 1,339 g/t Ag and 1.21 g/t Au and its Candelaria Project in west central Nevada. More >

Co. Provides Ground-Floor Opportunity in Precision Oncology
Source: Joseph Pantginis  (8/15/22)
Nuvectis Pharma Inc recently announced quarterly financial results and is continuing to advance its precision oncology programs. H.C. Wainwright & Co. LLC advised in an earnings update that the firm offers significant upside potential as it is rapidly advancing its drug candidates through clinical development and is looking for ways to expand to markets outside of the U.S. H.C. Wainwright stated that it is reiterating its Buy rating and $21 price target for Nuvectis Pharma. More >

HSCT/Gene Therapy Co. Sees Many Positive Catalysts in Q422
Source: Yun Zhong  (8/15/22)
Hematopoietic stem cell transplantation (HSCT) and gene therapy firm Magenta Therapeutics Inc. recently announced updates related to two of its leading clinical programs. BTIG LLC advised in a research update that it expects Magenta to release updated clinical data from its MGTA-117 and MGTA-145 programs in Q4/22, which will serve as key catalysts for the company. BTIG stated it is reiterating its "Buy" rating and $6/share price target on Magenta Therapeutics. More >

Biotech Co. Nearing Milestones for HBV Drugs
Source: Ed Arce  (8/15/22)
Arbutus Biopharma Corp. presented clinical data to an international liver disease conference showing that its AB-729 continues to deliver strong reductions in HBsAg. The company is now conducting three separate combination therapy studies of its AB-729 and expects to achieve important milestones when the initial data readouts are released in H2/22. H.C. Wainwright & Co. affirmed its Buy rating for Arbutus Biopharma and adjusted its price target to $7.50. More >

Healthcare Co. Enters US Alcohol Addiction Treatment Market
Source: Streetwise Reports  (8/15/22)
One analyst says this healthcare co. has the opportunity to generate attractive CAPEX-light, high margin SaaS-like recurring revenues, which investors are currently getting for free, after the biotech firm entered the US market for alcohol addiction treatment through off-label licensing deals with a network of treatment clinics. More >

Expert Expects Life Science Co. To Do Exceptionally Well
Source: Penny Queen  (8/15/22)
Avivagen is an early-stage life sciences company with a patented product for immune support that causes dramatic and profitable improvements in livestock. They have been increasing their sales and market penetration at a dramatic rate, and I believe them to be at an inflection point. Research coverage is expecting a 7x return.
More >

Rare Earths Co. Raises AU$45 Million
Source: Michael Bentley  (8/15/22)
These funds, including US$30M from a strategic investor, should see Vital Metals Ltd. through extraction facility commissioning, now underway, noted an MST Access report. More >

Firm Sees Boost in Sales of Health Chewable for Dogs
Source: Joseph Gomes   (8/15/22)
Recent orders from Avivagen Inc. are helping the developer of this product build a recurring revenue stream, noted a Noble Capital Markets report. More >